Citation: Ue. Vu et al., Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: Potentials for therapeutic use, LEUK LYMPH, 39(5-6), 2000, pp. 573-582
Authors:
Bishop, MR
Tarantolo, SR
Pavletic, ZS
Lynch, JC
Morris, ME
Zacharias, D
Armitage, JO
Kessinger, A
Citation: Mr. Bishop et al., Filgrastim as an alternative to donor leukocyte infusion for relapse afterallogeneic stern-cell transplantation, J CL ONCOL, 18(11), 2000, pp. 2269-2272
Authors:
Pavletic, ZS
Arrowsmith, ER
Bierman, PJ
Goodman, SA
Vose, JM
Tarantolo, SR
Stein, RS
Bociek, G
Greer, JP
Wu, CD
Kollath, JP
Weisenburger, DD
Kessinger, A
Wolff, SN
Armitage, JO
Bishop, MR
Citation: Zs. Pavletic et al., Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia, BONE MAR TR, 25(7), 2000, pp. 717-722
Authors:
Bishop, MR
Tarantolo, SR
Geller, RB
Lynch, JC
Bierman, PJ
Pavletic, ZS
Vose, JM
Kruse, S
Dix, SP
Morris, ME
Armitage, JO
Kessinger, A
Citation: Mr. Bishop et al., A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation, BLOOD, 96(1), 2000, pp. 80-85
Authors:
Bennett, CL
Waters, TM
Stinson, TJ
Almagor, O
Pavletic, ZS
Tarantolo, SR
Bishop, MR
Citation: Cl. Bennett et al., Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation, BONE MAR TR, 24(5), 1999, pp. 555-560